Back to top

Tale of the Tape

Zacks Equity Research

Kindred Biosciences (KIN) Looks Good: Stock Gains 5.6%
October 04, 2016


Trades from $3

Kindred Biosciences, Inc. (KIN - Snapshot Report) was a big mover last session, as the company saw its shares rise almost 6% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $4.32 to $5.18 in the past one-month time frame.

In the last 30 days, the company has seen no estimate revision and the Zacks Consensus Estimate also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.      

Kindred Biosciences currently holds a Zacks Rank #2 (Buy), while its Earnings ESP is 0.00%.

Another well-ranked Biomeical/Gene stock is Achillion Pharmaceuticals, Inc. (ACHN - Analyst Report) , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is KIN going up? Or down? Predict to see what others think: Up or Down

Confidential from Zacks

Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>